INTRODUCTION
============

India is one of the largest and most populated countries in the world, with over a billion inhabitants. There are currently an estimated 2.4 million Indians living with HIV/AIDS \[[@R1]\]. Although HIV infection emerged as late as 1986 in India, later than it did in many other countries, the infection rates rose sharply throughout the 1990s. In 1987 the Government of India launched a National AIDS Control Programme (NACP) to co-ordinate national responses which covered surveillance, blood screening, and health education \[[@R2]\]. By the end of 1987, of the 52,907 people tested, 135 people were found to be HIV positive and 14 had AIDS. Most of these initial cases had occurred through heterosexual sex. But at the end of the 1980s a rapid spread of HIV was observed among injecting drug users in Manipur, Mizoram and Nagaland - three north-eastern states of India bordering Myanmar (Burma). At the beginning of the 1990s, as infection rates continued to rise, responses were proportionately strengthened. In 1992, the Government of India set up the National AIDS Control Organisation (NACO), to oversee the formulation of policies, prevention work and control programmes relating to HIV and AIDS \[[@R2]\]. In the same year, the Government of India launched a Strategic Plan for HIV prevention. This plan established the administrative and technical basis for programme management and also set up State AIDS bodies in 25 states and 7 union territories \[[@R3]\]. It was able to make a number of important improvements in HIV prevention such as improving blood safety *etc.* \[[@R3]\].

It is now clear that although individual states and cities in India had separate epidemics, HIV had spread to the general population by the 1990s. Currently, the epidemic affects all sectors of Indian society, even those initially considered not at risk \[[@R4]\].

TREATMENT FOR PEOPLE LIVING WITH HIV
====================================

Antiretroviral drugs (ARVs), which can significantly delay the progression from HIV to AIDS -- have been available in developed countries since 1996 \[[@R5]\]. There are currently over 30 ARVs available globally \[[@R6]\]. These include largely NRTIs, NNRTIs, Protease inhibitors, the new Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and HIV integrase strand transfer inhibitors -- both single drugs and fixed dose combinations (FDCs) (Table **[1](#T1){ref-type="table"}**). The major originator companies include: Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec \[[@R7]\]. The availability of ARV drugs began in 1987 with the zidovidine and the latest ones to be approved in 2007 are the Maraviroc \[[@R8]\] and Raltegravir \[[@R9]\] potassium marketed as Selzentry (Pfizer) and Isentress (Merck) respectively.

There are about 30 ARV drugs available in India (Table **[2](#T2){ref-type="table"}**). Data show that almost all classes of drugs are manufactured and sold by the generic manufacturers *viz.,* Aurobindo, Hyderabad, Andhra Pradesh; Cipla Limited, Verna Industrial Estate, Goa; Emcure Pharmaceuticals, Pune, Maharashtra; Hetero Drugs, Hyderabad, Andhra Pradesh; Macleods Pharmaceuticals, Kachigam, Daman; Matrix Laboratories, Nashik, Maharashtra; Ranbaxy, Sirmour, Himachal Pradesh; and Strides Arcolab, Anekal Taluk, Bangalore.

The drugs available in India thus include both single drug and FDCs covering both the first line and second line ARVs \[[@R10]-[@R12]\]. The Government of India launched the free antiretroviral treatment (ART) programme in 2004, starting with eight tertiary-level government hospitals in the six high-prevalence states of India \[[@R3]\]. All persons with HIV infection who are clinically eligible to receive ART are included in the Phase I of the programme. The subgroups of the people living with HIV/AIDS (PLHA) targeted on a priority basis include: (i) sero-positive mothers who have participated in the prevention of parent-to-child transmission (PPTCT) programme; (ii) sero-positive children below the age of 15 years; and (iii) people with AIDS who seek treatment in government hospitals \[[@R3]\]. The free ART programme envisages a comprehensive prevention, care and treatment programme, with i) standardized, simplified combination of ART regimens; ii) regular secure supply of good-quality ARV drugs; and iii) a robust monitoring and evaluation system eventually working towards universal access to care and treatment \[[@R3]\].

Linkages and referrals to other programmes as the prevention of parent-to-child transmission (PPTCT), programme are also being strengthened to enable women and children living with HIV/AIDS have greater access to treatment. The Phase I programme is also establishing linkages with other related national programmes as the Revised National Tuberculosis Control Programme (RNTCP), Reproductive and Child Health (RCH) Programme and the massive National Rural Health Mission (NRHM) \[[@R3]\].

ACCESS TO ARVs IN INDIA
=======================

Currently there are over 160 ART ARV centers in 31 States and Union Territories \[[@R6]\] with an estimated 140,000 patients are receiving ARVs free of cost at these centers \[[@R13]\]. Another 35,000 patients are receiving free ARVs at ART centers run by NGOs and other organizations \[[@R3]\]. The ART centres are being scaled up in a phased manner to provide free ARVs to 100,000 patients by the end of 2007 and 300,000 patients by 2011 in 250 centres across India under phase III of NACO \[[@R13]\]. ARV drugs including combination containing ingredients for adults are: i) Two drug combination tablets containing Stavudine and Lamivudine; ii) Two drugs combination tablets containing Zidovudine and Lamivudine; iii) Three drugs combination tablets containing Stavudine, Lamivudine and Nevirapine; iv) Three drug combination tablets containing Zidovudine, Lamivudine and Nevirapine; v) Efavirenz \[[@R3]\]. The following drugs are used for pediatric HIV management for children weighing up to 20 kg: FDCs i) Stavudine and Lamivudine; ii) Stavudine and Lamivudine; iii) Stavudine, Lamivudine and Nevarapine; iv) Stavudine, Lamivudine and Nevarapine; and v) Efavirenz \[[@R4]\]. But some drugs are still not available in India as single drugs, as per our analysis (Table **[3](#T3){ref-type="table"}**). These include four protease inhibitors (Agenerase, Aptivus, Lexiva, and Prezista), one NNRTI (Rescriptor) and one Fusion inhibitor (Fuzeon) \[[@R7], [@R14]\].

Thus, only about 150,000 people with HIV/AIDS access the ARVs from the public sector while some also get these through private health facilities, which dominate India's healthcare sector. But the vast majority of 2.4 million PLHA cannot afford to buy treatment privately. While the coverage of treatment continues to remain unacceptably low, improvements are being made to expand access to ARVs in a number of areas \[[@R15]\]. This is a massive challenge for the NACO, Govt. of India.

The HIV/AIDS is a chronic disease requiring lifelong treatment with different ARV combinations compounding the problem for people who also develop drug resistance and side effects over time \[[@R16]\]. Thus, increasing access to ARVs also means that an increasing number of people living with HIV in India are likely to develop resistance to the first line treatment necessitating switching over to the second line ARVs. Data from Africa show that over a five year period 22% people needed such a switch-over \[[@R16]\]. In addition, another study from South Africa found that within 3 years on ART, 21% of patients who had started a d4T-based regimen needed to be switched because of toxicity \[[@R17]\]. This resulted in a 2006 recommendation by the WHO to move away from d4T to less toxic combinations based on either AZT or tenofovir \[[@R18]\], of course with a significant price implications. In 2008, the NACO began to roll out government funded second-line anti-retroviral treatment in two centres in Mumbai and Chennai \[[@R6]\]. There are also plans to improve the provision of nevirapine to pregnant mothers with HIV, which can significantly reduce the risk that they will pass infection on to their child \[[@R6]\]. In common with other parts of the developing world, the second line ARV treatment in India is currently prohibitively more expensive than the first line treatment which is essentially based on the generics.

Despite several global initiatives to provide ARV treatment in poor and middle income countries, like the 3 by 5 and the current efforts towards Universal Access, the outreach is still poor with the targets well behind with coverage of an estimated 3 million or about 31% of the 9.7 million needing the ARVs \[[@R15], [@R16]\]. What is more, about 2.5 million new infections were added during 2007 underscoring the massive task ahead. Another matter of serious concern is the estimated 2.1 million children under 15 years needing treatment while the coverage is about 10% only \[[@R15]\]. Funding for the purchase of the drugs remains a serious constraint with the gap between required and available resources of US\$8.1 billion during 2007. To meet the universal targets, funding needs to be enhanced to at least four times to US\$ 35 billion in 2010 and to US\$41 billion in 2015 \[[@R15]\]. One critical factor continues to be the cost of ARVs \[[@R15]\].

IMPACT OF NEW PATENT REGIMES
============================

In the light of the new TRIPS-complaint IP regime \[[@R19]\] in India and other developing countries and the need to find innovative strategies to provide ARVs, there is a need to have a serious look at whether the strong IP protection system is a barrier. We therefore looked at the patent profile of ARV drugs both in India and the USPTO filed by the originator companies. Table **[4](#T4){ref-type="table"}** shows data on the patent profile of FDA approved ARVs. We could track 93 patents on ARVs filed in the USPTO by the originator companies. The major patent filers were Abbot, Gilead, Abbott, GSK *etc.* with the number of patents filed varying with the drug. For example, Abbott filed as many as 20 patents on Lopinavir-Ritonavir (sold as Kaletra). For combinations as Atripla (Efavirenz and Emtricitabine and Tenofovir Disoproxil fumerate), Gilead filed as many as 15 patents. Similarly, Gilead also filed 10 patents on Truvada (Emtricitabine and Tenofovir Disoproxil fumarate). Data on break-up of the patents filed at the USPTO show that Gilead holds the maximum (25) patents followed by Abbott with 20, GSK with 17, Tibotec 5 *etc*., (Table **[5](#T5){ref-type="table"}**).

Significantly, most generic antiretroviral agents currently now being used in Africa and Asia are manufactured in India as the Indian Patent Act (1970) permitted making generic copies of drugs in India \[[@R20]\]. With the largest global standard facilities for manufacturing outside the USA, the Indian companies were able to offer HIV drugs at a fraction of the cost of brand-name drugs. The new Indian patent Act (2005) has already created significant barriers for the development of new generics on ARVs patented in India after 2005 \[[@R21]\]. Developing countries had to allow inventors to file patent applications from January 1, 1995, and the decision on whether or not to grant any patent could be taken at the end of the transition period. This has potentially serious impact on global initiatives of MSF, PEPFAR, Clinton Foundation *etc* which source drugs from the Indian companies for distribution in African countries \[[@R20]\].

There are also apprehensions that the first-line antiretroviral drug regimens in wide use may soon be found wanting to meet the needs of HIV-infected patients \[[@R22]\]. There is also evidence to show that some people may be intolerant to some drugs as also reports of contraindications that need attention \[[@R18], [@R23]\]. More importantly, there could be treatment failure necessitating drugs outside the available ARV drug regimens. In addition, without strong second-line therapeutic regimens HIV patients could well stand to lose the benefits of antiretroviral therapy. Worse still, they may transmit the drug-resistant virus to others compounding the problem. \"Sustaining\" may well soon surpass with \"scaling up\" of antiretroviral therapy emerging as the major challenge \[[@R22]\]. Brazil is already facing this challenge, and African and Asian countries with far fewer resources will probably encounter even greater hurdles in gaining access to second-line therapies \[[@R22]\].

The impact of Trade Related Aspects of Intellectual Property Rights (TRIPs)-complaint legislation \[[@R19], [@R21]\] on access to ARVs to HIV-infected persons in resource-limited countries therefore cannot be overemphasized. There is a need to find solutions and find them fast. A dual approach may be required i) ensure the continued availability of high quality generics by manufacturers from India and elsewhere; and ii) encourage strong efforts towards developing new generics from patented drugs and new formulations through newer global strategies. For example, the US FDA has approved, under PEPFAR, several generic antiretroviral preparations for purchase and use outside the United States \[[@R10]\].

There have been a few attempts by the originator companies, under intense criticism on their pricing policies, to license the ARV drugs. Table **[6](#T6){ref-type="table"}** shows data on licensing of ARV drugs by the originator companies to non-US companies, mostly in South Africa, other African countries and India. GSK has licensed to maximum companies outside the US -- 4 companies in the African continent. The BMS has licensed its drugs stavudine and didanosine to over 49 countries including India. Some companies like Gilead have licensed manufacture of its drugs to a large number of generic companies in India through non-exclusive licensing \[[@R24]\].

OPTIONS TO PROMOTE ACCESS TO NEWER ARVs
=======================================

A priority now is to, among others, find less toxic first-line ARV combinations and drug options when resistance is developed \[[@R23]\]. The primary issue continues to be strong TRIPS-complaint global patenting regimes which impact the key generics-producing countries such as India, Brazil, and Thailand. The MSF estimates that the ARV prices are unlikely to see the dramatic 99% drop seen for the currently used first-line ARVs - from \>\$10,000 per patient per year in 2000 to \$87 today \[[@R16]\]. National Governments of developing countries will therefore have difficult choices before them like whether to treat more number of patients on more affordable ARV combinations, or fewer people on less toxic but more expensive combinations.

Simple switching over from the most commonly used d4T-based first-line ARV combination to a less toxic option involves about twice the cost \[[@R23]\]. And changing over to a TDF-based ARV regimen would mean a 4-11 fold price increase \[[@R23]\]. According to MSF's estimates, replacing d4T with a TDF-based regimen for all patients from 2008 to 2014 (based on today's prices) would mean a 4-11 fold price increase \[[@R16], [@R25]\]. Unless there are overall price reductions the overall increase of cost for ARVs. in some middle-income countries could be as high as 17-fold \[[@R16]\].

Besides the availability of generics for the first-line ARVs in countries with manufacturing capacity like India, Brazil, and Thailand, multiple producers and the resultant competition has actually brought down prices dramatically \[[@R16]\]. Globally, India is considered the "pharmacy of the developing world," as charities like MSF source over 80% of its ARVs from India as also other ARV providers like the Clinton Foundation, PEPFAR *etc.*\[[@R16], [@R20]\]*.* This was possible only because the pre-TRIPS patent regimes allowed the development of single drugs and FDCs, an innovation that not just simplified HIV/AIDS treatment but helped significant scale-ups. In the recent years, there have been aggressive patenting by originator companies in countries like India, Brazil and Thailand \[[@R26]-[@R28]\].

The global battle for affordable ARVs, thus is likely to get tougher in future. Developing countries with significant PLHA need to use all the means available including public health safeguards and flexibilities enshrined in the WTO TRIPS as reiterated in the Doha Declaration \[[@R29]\] that allows countries to overcome patent barriers by issuing compulsory licenses (CLs) to open the market to competition despite patent protection.

Other options open to sovereign countries include design or interpret national patent laws to limit the scope of patentability of new chemical entities with a public health priority and other strategies \[[@R30], [@R31]\]. Like, for example, the Indian Patents Act (2005) that allows pre-grant opposition \[[@R32]\]. In June 2008 such an opposition was successfully contested in India for the pediatric syrup formulation of NVP as the Indian patent office rejected the patent \[[@R26]-[@R28]\].

PATENT POOLS
============

In what is considered a path-breaking development, the UNITAID decided in principle in July 2008 to establish a patent pool for ARVs \[[@R33]\] that may hold the key for access to affordable newer ARVs in the future. This concept was originally mooted by the MSF, along with Essential Inventions to the UNITAID board in June 2006 to overcome the difficulties to access newer ARVs. As Ellen t'Hoen of the UNITAIDS explains \[[@R34]\]: "A patent pool is a mechanism whereby patent owners put their patents in a 'pool' and allow others who need access to those patents to use them in exchange for a royalty payment. Patent pools have, in fact, been used to drive forward innovation in many different fields of technology, for example in the development of recording equipment, where you need multiple patents to be able to produce a certain product". Hoen considers that the patent pooling as a strategy will not only help the development of new fixed-dose combination drugs that combine multiple compounds into one pill, especially for the newer drugs and in developing fixed-dose combinations or paediatric formulations \[[@R34]\].

The advantages of patent pool appear to be huge. Like, for example, the development of pediatric formulations or the much-needed FDCs for less toxic first and second-line treatments. Patent filed by originator companies on individual compounds typically hamper the development of FDCs, a barrier that a patent pool would help break. Generic versions of new drugs also could be developed quickly through the patent pool as the generic companies need not wait for the 20-year patent expiration. If the patent pool is accessed by multiple companies, the resultant competition should drive down the price, as seen for the current first line ARVs. What is more, these drugs could be exported to poor countries with HIV/AIDS load that have no manufacturing capability by countries like India, Brazil and Thailand. All these could be built into the licensing agreements with the originator companies that own the patents. But this can become successful only if the patent owning companies are willing to put their patents into the pool. Efforts are on at the UNITAID to work out the modalities of operating the proposed patent pool. In fact the recently concluded WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property of the Inter-Governmental Working Group on Public Health and Innovation \[[@R35]\] had recommended exploring the feasibility of patent pools for diseases of the poor \[[@R36]\]. By the end of 2009, the UNITAID pool is eventually expected to run as a separate entity \[[@R37]\].

The need for affordable ARVs to vulnerable sections of society like children, pregnant women and people with HIV-TB in resource-poor countries cannot be overemphasized. The urgency is especially for the paediatric populations as, of the 22 ARVs approved by the US FDA for adults, as many as 8 are not approved for use in children while 9 do not have any pediatric formulations \[[@R38]\].
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###### 

Total Antiretroviral Drugs Available

  S. No.   Class                                          Drug         Company                                                                         Year of Approval   Remarks   
  -------- ---------------------------------------------- ------------ ------------------------------------------------------------------------------- ------------------ --------- ------------------------
  1        NRTI                                           Retrovir     Zidovudine (AZT)                                                                GSK                1987      
  2        NRTI                                           Epivir       Lamivudine (3TC)                                                                GSK                1995      
  3        NRTI                                           Zerit        Stavudine (d4T)                                                                 BMS                1994      
  4        NRTI                                           Videx        Didanosine (ddl)                                                                BMS                1989      
  5        NRTI                                           Videx EC     enteric coated didanosine (ddI EC)                                              BMS                2000      
  6        NRTI                                           Ziagen       Abacavir (ABC)                                                                  GSK                1988      
  7        NRTI                                           Viread       Tenovofir Disoproxil Fumarate (TDF)                                             Gilead             2002      
  8        NRTI                                           Emtriva      Emtricitabine (FTC)                                                             Gilead             2003      
  9        NRTI                                           Trizivir     abacavir, zidovudine, and lamivudine (ABC, AZT and 3TC)                         GSK                2000      3NRTI
  10       NRTI                                           Combivir     lamivudine and zidovudine (3TC and AZT)                                         GSK                1997      2 NRTI
  11       NRTI                                           Epzicom      abacavir and lamivudine (ABC and 3TC)                                           GSK                2004      2 NRTI
  12       NRTI                                           Truvada      tenofovir disoproxil fumarate and emtricitabine (TDF and FTC)                   Gilead             2004      2 NRTI
  13       NNRTI                                          Viramune     Nevirapine (NVP)                                                                BI                 1996      
  14       NNRTI                                          Sustiva      Efavirenz (EFV)                                                                 BMS                1998      
  15       NNRTI                                          Rescriptor   Delavirdine (DLV)                                                               Agouron            2003      
  16       NNRTI                                          Intelence    Etravirine                                                                      Tibotec            2008      
  17       NNRTI+NRTI                                     Atripla      efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV, FTC and TDF)   Gilead             2006      NNRTI+NRTI combination
  18       PI                                             Crixivan     Indinavir (IDV)                                                                 Merck              1996      
  19       PI                                             Viracept     Nelfinavir (NFV)                                                                Agouron            1997      
  20       PI                                             Invirase     Saquinavir (SQV)                                                                Roche              1997      Withdrawn 2005
  21       PI                                             Norvir       Ritonavir (RTV)                                                                 Abbott             2000      
  22       PI                                             Agenerase    Amprenavir (APV)                                                                GSK                1997      Withdrawn 2007
  23       PI                                             \-           Lopinavir (LPV)                                                                 \-                 2000      
  24       PI                                             Kaletra      Lopinavir (LPV)+Ritonavir (RTV)                                                 Abbott             2005      2 PI
  25       PI                                             Reyataz      Atazanavir (ATV)                                                                BMS                2003      
  26       PI                                             Lexiva       Foseamprenavir                                                                  GSK                2003      
  27       PI                                             Prezista     Darunvir ethanolate                                                             Tibotec            2006      
  28       PI                                             Aptivus      Tipranavir (TPV)                                                                BI                 2005      
  29       Fusion Inhibitor                               Fuzeon       Enfuvirtide (T-20)                                                              Roche              2003      
  30       Entry Inhibitors-CCR5 co-receptor antagonist   Selzentry    Maraviroc                                                                       Pfizer             2007      
  31       HIV integrase strand transfer inhibitors       Isentress    Raltegravir Potassium                                                           Merck              2007      

Source:

HIV prevelance data\\USFDA Approved HIV AIDS Drug updated 14/05/2009Electronic Orange Book updated Feb, 2009

###### 

Antiretroviral Drugs Available in India

  S. No.   Class                                          Drug (Active Ingredient)                                                                          Company                                                                                                                                                                                                                                                          Remarks
  -------- ---------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  1        NRTI                                           Zidovudine (AZT)\*                                                                                Ranbaxy (Sirmour, Himachal Pradesh), Aurobindo (Hyderabad, Andhra Pradesh), Cipla (Verna Industrial Estate, Goa), Matrix Laboratories (Nashik, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh)                                                            Second Line
  2        NRTI                                           Lamivudine (3TC) [\#](#T2FN2){ref-type="table-fn"}                                                Ranbaxy (Sirmour, Himachal Pradesh), Cipla Limited (Verna Industrial Estate, Goa), Matrix Laboratories (Nashik, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh), Macleods Pharmaceuticals (Kachigam, Daman)                                               Second Line
  3        NRTI                                           Stavudin (d4T)\*                                                                                  Aurobindo (Hyderabad, Andhra Pradesh), Matrix Laboratories (Nashik, Maharashtra), Cipla (Verna Industrial Estate, Goa), Emcure Pharmaceuticals (Pune, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh)                                                     \-
  4        NRTI                                           Didanosine (ddl)\*                                                                                Aurobindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                                                            Second Line
  5        NRTI                                           Abacavir sulfate (ABC) [\#](#T2FN2){ref-type="table-fn"}                                          Aurobindo (Hyderabad, Andhra Pradesh), Matrix Laboratories (Nashik, Maharashtra)                                                                                                                                                                                 Second Line
  6        NRTI                                           Emtricitabine (FTC) [\#](#T2FN2){ref-type="table-fn"}                                             Aurbindo (Hyderabad, Andhra Pradesh), Matrix Laboratories (Nashik, Maharashtra)                                                                                                                                                                                  \-
  7        NRTI                                           Tenofovir disoproxil fumarate (TDF) [\#](#T2FN2){ref-type="table-fn"}                             Matrix Laboratories (Nashik, Maharashtra)                                                                                                                                                                                                                        Second Line
  8        NRTI                                           Abacavir, zidovudine, and lamivudine (ABC, AZT and 3TC) [\#](#T2FN2){ref-type="table-fn"}         Aurbindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                                                             3NRTI; Trizivir US brand name in Indian generic FDC manufactured; First Line
  9        NRTI                                           Lamivudine and zidovudine (3TC and AZT) [\#](#T2FN2){ref-type="table-fn"}                         Aurobindo (Hyderabad, Andhra Pradesh), Pharmacare Ltd, Cipla (Verna Industrial Estate, Goa), Emcure Pharmaceuticals Limited (Pune, Maharashtra), Matrix Laboratories (Nashik, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh)                             2 NRTI; Combivir US brand name in Indian generic FDC manufactured; First Line
  10       NRTI                                           Abacavir and lamivudine (ABC and 3TC) [\#](#T2FN2){ref-type="table-fn"}                           Aurobindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                                                            2 NRTI; Epzicom US brand name in Indian generic FDC manufactured
  11       NRTI                                           Tenofovir disoproxil fumarate and emtricitabine (TDF and FTC) [\#](#T2FN2){ref-type="table-fn"}   Matrix Laboratories (Nashik, Maharashtra), Aurobindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                 2 NRTI; Truvada US brand name in Indian generic FDC manufactured; Second Line
  12       2 NRTI                                         Lamivudine+Tenofovir Disoproxil Fumarate [\#](#T2FN2){ref-type="table-fn"}                        Matrix Laboratories (Nashik, Maharashtra)                                                                                                                                                                                                                        \-
  13       2 NRTI                                         Abacavir Sulfate+Lamivudine [\#](#T2FN2){ref-type="table-fn"}                                     Aurobindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                                                            
  14       3 NRTI                                         Lamivudine+Zidovudine+Abacavir Sulfate [\#](#T2FN2){ref-type="table-fn"}                          Aurbindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                                                             First Line
  15       NNRTI                                          Nevirapine (NVP) [\#](#T2FN2){ref-type="table-fn"}                                                Ranbaxy (Sirmour, Himachal Pradesh), Aurobindo (Hyderabad, Andhra Pradesh), Cipla (Verna Industrial Estate, Goa), Strides Arcolabs (Anekal Taluk Bangalore), Hetero Drugs (Hyderabad, Andhra Pradesh), Matrix Laboratories (Nashik, Maharashtra)                 First Line
  16       NNRTI                                          Efavirenz (EFV) [\#](#T2FN2){ref-type="table-fn"}                                                 Aurobindo (Hyderabad, Andhra Pradesh), Cipla Limited (Verna Industrial Estate, Goa), Strides Arcolab (Anekal Taluk Bangalore), Matrix Laboratories (Nashik, Maharashtra), Emcure Pharmaceuticals (Pune, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh)   First Line
  17       NNRTI                                          Etravirine [\#](#T2FN2){ref-type="table-fn"}                                                      Johnson & Johnson                                                                                                                                                                                                                                                204028; mail-box application no. IN/PCT/2001/00436/MUM
  18       NNRTI+NRTI                                     Efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV, FTC and TDF)                     Viraday is manufactured by Cipla                                                                                                                                                                                                                                 NNRTI+NRTI combination; Atripla US brand name in Indian generic FDC called viraday \[[2](#T2FN6){ref-type="table-fn"}\]
  19       2 NRTI+NNRTI                                   Stavudine+Lamivudine+Efavirenz [\#](#T2FN2){ref-type="table-fn"}                                  Strides Arcolab (Anekal Taluk Bangalore)                                                                                                                                                                                                                         First Line
  20       2 NRTI+NNRTI                                   Lamivudine+Zidovudine+Efavirenz [\#](#T2FN2){ref-type="table-fn"}                                 Strides Arcolab (Anekal Taluk Bangalore), Aurobindo (Hyderabad, Andhra Pradesh)                                                                                                                                                                                  First Line
  21       2 NRTI+NNRTI                                   Lamivudine+Zidovudine+Nevirapine [\#](#T2FN2){ref-type="table-fn"}                                Aurobindo (Hyderabad, Andhra Pradesh), Cipla Limited (Verna Industrial Estate, Goa), Strides Arcolab (Anekal Taluk Bangalore)                                                                                                                                    First Line
  22       2 NRTI+NNRTI                                   Lamivudine+Stavudine+Nevirapine [\#](#T2FN2){ref-type="table-fn"}                                 Strides Arcolab (Anekal Taluk Bangalore)                                                                                                                                                                                                                         First Line
  23       PI                                             Indinavir (IDV) [\#](#T2FN2){ref-type="table-fn"}                                                 Cipla (Verna Industrial Estate, Goa), Emcure (Pune, Maharashtra), Hetero Drugs (Hyderabad, Andhra Pradesh), Ranbaxy (Sirmour, Himachal Pradesh)                                                                                                                  Second Line
  24       PI                                             Nelfinavir (NFV) [\#](#T2FN2){ref-type="table-fn"}                                                Cipla (Verna Industrial Estate, Goa), Hetero Drugs (Hyderabad, Andhra Pradesh), Macleods Pharmaceuticals (Kachigam, Daman)                                                                                                                                       Second Line
  25       PI                                             Ritonavir (RTV) [\#](#T2FN2){ref-type="table-fn"}                                                 Cipla (Verna Industrial Estate, Goa), Hetero Drugs (Hyderabad, Andhra Pradesh)                                                                                                                                                                                   Second Line
  26       PI                                             Lopinavir/Ritonavir [\#](#T2FN2){ref-type="table-fn"}                                             Matrix Laboratories (Nashik, Maharashtra), Aurobindo (Hyderabad, Andhra Pradesh), Cipla (Verna Industrial Estate, Goa)                                                                                                                                           Second Line
  27       PI                                             Atazanavir (ATV) [\#](#T2FN2){ref-type="table-fn"}                                                Emcure Pharmaceuticals (Pune, Maharashtra)                                                                                                                                                                                                                       Second Line
  28       PI                                             Darunavir[\*\*](#T2FN3){ref-type="table-fn"}                                                      Emcure Pharmaceuticals (Pune, Maharashtra)                                                                                                                                                                                                                       Second Line
  28       Fusion Inhibitor                               Nil                                                                                                                                                                                                                                                                                                                                                                Nil
  29       Entry Inhibitors-CCR5 co-receptor antagonist   Maraviroc                                                                                                                                                                                                                                                                                                                                                          Patent granted in India;204132; mail-box Application No. 885/BOM/1999; Drug registration in process \[[1](#T2FN5){ref-type="table-fn"}\] Second Line
  30       HIV integrase strand transfer inhibitors       Reltegravir Potassium                                                                                                                                                                                                                                                                                                                                              Patent granted in India; 212400; mail-box application no. 868/CHENP/2004

Approved Drugs;

Tentatively Approved.

Registration pending with the Indian Drug Controller.

**Explanation for classifying drugs (active ingredient) as First Line & Second Line**

single drug- First Line- National AIDS Control Organization (NACO); National Program.

single drug- Second Line- Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: A Public Health Approach.

FDC- First Line- NACO+WHO guidelines.

FDC- Second Line- WHO guidelines.

Source:

[www.jipmer.edu/charu/v4issue1.pdf](www.jipmer.edu/charu/v4issue1.pdf)

<http://pharmacy.around-world.biz/drugs/Atripla.html>

USFDA: HIV prevalence data\\President\'s Emergency Plan for AIDS Relief updated 14/05/2009.

Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach (First & Second Line).

###### 

ART Drugs Not Available in India as Single Drug

  S. No.   Brand Name                                  Class              Generic                           Company Manufacturing   Applicant                        Assignee
  -------- ------------------------------------------- ------------------ --------------------------------- ----------------------- -------------------------------- -------------------------------
  1        Rescriptor                                  NNRTI              Delavirdine (DLV)                 Agouron (USA)           Pfizer (USA)                     Pharmacia & Upjohn Co
  2        Agenerase                                   PI                 Amprenavir (APV)                  GSK (UK)                GSK (UK)                         Vertex Pharma GSK
  3        Aptivus                                     PI                 Tipranavir (TPV)                  BI (Germany)            BI (Germany)                     Pharmacia and Upjohn Co.
  4        Lexiva                                      PI                 Fosamprenavir Calcium (FOS-APV)   GSK (UK)                GSK (UK)                         Vertex Pharmaceuticals
  5        Prezista[\*](#T3FN2){ref-type="table-fn"}   PI                 Darunavir Ethanolate              Tibotec (USA),          Tibotec (USA)                    Tibotec (USA)
  6        Fuzeon                                      Fusion Inhibitor   Enfuvirtide (T-20)                Roche (Switzerland)     Roche (Switzerland) & Trimeris   Duke University Trimeris Inc.

Source:

HIV prevalence data/USFDA Approved HIV AIDS Drug Updated January 2008.Electronic Orange Book.United States Patent & Trade Mark Office.

Registration pending with the Indian Drug Controller.

###### 

Patent Profile of FDA Approved Drugs

  S. No.   U.S. Patent No.   Active Ingredient                                         Proprietary   Applicant   Class                                          Year of Filing   Patent Expiration
  -------- ----------------- --------------------------------------------------------- ------------- ----------- ---------------------------------------------- ---------------- -------------------
  1        5585397           Amprenavir                                                Agenerase     GSK         PI                                             24-Nov-93        17-Dec-2013
  2        5646180           Amprenavir                                                Agenerase     GSK         PI                                             5-Dec-95         8-Jul-2014
  3        5723490           Amprenavir                                                Agenerase     GSK         PI                                             19-Apr-95        3-Mar-2015
  4        6730679           Amprenavir                                                Agenerase     GSK         PI                                             20-Mar-97        11-Nov-2017
  5        6436989           Fosamprenavir Calcium                                     Lexiva        GSK         PI                                             24-Dec-97        24-Dec-2017
  6        6514953           Fosamprenavir Calcium                                     Lexiva        GSK         PI                                             20-Apr-01        15-Jul-2019
  7        5849911           Atazanavir Sulfate                                        Reyataz       BMS         PI                                             9-Apr-97         20-Jun-2017
  8        6087383           Atazanavir Sulfate                                        Reyataz       BMS         PI                                             21-Dec-98        21-Dec-2018
  9        5843946           Darunavir Ethanolate                                      Prezista      Tibotec     PI                                             24-Aug-93        1-Dec-2015
  10       6248775           Darunavir Ethanolate                                      Prezista      Tibotec     PI                                             8-Apr-99         13-Aug-2014
  11       6335460           Darunavir Ethanolate                                      Prezista      Tibotec     PI                                             22-Feb-00        25-Aug-2012
  12       5413999           Indinavir Sulfate                                         Crixivan      Merck       PI                                             7-May-93         9-May-2012
  13       6645961           Indinavir Sulfate                                         Crixivan      Merck       PI                                             4-Mar-98         4-Mar-2018
  14       5541206           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             25-Apr-95        30-Jul-2013
  15       5635523           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             6-Apr-95         3-Jun-2014
  16       5648497           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             24-Mar-95        15-Jul-2014
  17       5674882           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             29-Mar-95        7-Oct-2014
  18       5846987           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             20-Mar-97        29-Dec-2012
  19       5886036           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             20-Mar-97        19-Nov-2013
  20       5914332           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             21-Nov-96        13-Dec-2015
  21       5948436           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             13-Mar-95        13-Sep-2013
  22       6037157           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             26-Jun-96        26-Jun-2016
  23       6232333           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             7-Nov-97         7-Nov-2017
  24       6284767           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             8-Dec-98         15-Feb-2016
  25       6458818           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             2-Jul-99         7-Nov-2017
  26       6521651           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             10-Sep-99        7-Nov-2017
  27       6703403           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             20-Sep-01        26-Jun-2016
  28       7141593           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             22-May-00        22-May-2020
  29       7432294           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             12-Oct-06        22-May-2020
  30       6911214           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             4-Sep-01         28-Nov-2021
  31       5484801           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             12-May-95        28-Jan-2014
  32       7148359           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             4-May-05         19-Jul-2019
  33       7364752           Lopinavir; Ritonavir                                      Kaletra       Abbott      PI                                             10-Nov-00        10-Nov-2020
  34       5484926           Nelfinavir Mesylate                                       Viracept      Agouron     PI                                             2-Feb-94         7-Oct-2013
  35       5952343           Nelfinavir Mesylate                                       Viracept      Agouron     PI                                             7-Jun-95         7-Oct-2013
  36       6162812           Nelfinavir Mesylate                                       Viracept      Agouron     PI                                             1-Apr-99         7-Oct-2013
  37       5196438           Saquinavir Mesylate                                       Invirase      Roche       PI                                             19-Nov-90        19-Nov-2010
  38       5852195           Tipranavir                                                Aptivus       BI          PI                                             4-Nov-96         22-Jun-2019
  39       6147095           Tipranavir                                                Aptivus       BI          PI                                             29-Oct-99        29-Oct-2019
  40       6169181           Tipranavir                                                Aptivus       BI          PI                                             9-Nov-98         6-May-2014
  41       6231887           Tipranavir                                                Aptivus       BI          PI                                             27-Jul-98        27-Jul-2018
  42       5034394           Abacavir Sulfate                                          Ziagen        GSK         NRTIs                                          22-Dec-89        18-Dec-2011
  43       5089500           Abacavir Sulfate                                          Ziagen        GSK         NRTIs                                          8-May-91         26-Jun-2009
  44       6294540           Abacavir Sulfate                                          Ziagen        GSK         NRTIs                                          1-Dec-99         14-May-2018
  45       6641843           Abacavir Sulfate                                          Ziagen        GSK         NRTIs                                          4-Aug-00         4-Feb-2020
  46       5047407           Abacavir Sulfate; Lamivudine                              Epzicom       GSK         NRTIs                                          8-Feb-89         17-Nov-2009
  47       5905082           Abacavir Sulfate; Lamivudine                              Epzicom       GSK         NRTIs                                          2-Jun-92         18-May-2016
  48       6417191           Abacavir Sulfate; Lamivudine                              Epzicom       GSK         NRTIs                                          30-Sep-97        28-Mar-2016
  49       7119202           Abacavir Sulfate; Lamivudine                              Epzicom       GSK         NRTIs                                          6-Jun-95         8-Feb-2009
  50       6004968           Lamivudine                                                Epivir        GSK         NRTIs                                          20-Mar-98        20-Mar-2018
  51       RE39155           Lamivudine                                                Epivir-Hbv    GSK         NRTIs                                          23-Jul-92        2-Jul-2013
  52       5859021           Lamivudine; Zidovudine                                    Combivir      GSK         NRTIs                                          22-Feb-96        15-May-2012
  53       5210085           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          22-Feb-91        11-May-2010
  54       5519021           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          2-Jun-95         21-May-2013
  55       5663169           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          2-Jun-95         2-Sep-2014
  56       5811423           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          12-Mar-97        7-Aug-2012
  57       5814639           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          16-Feb-93        29-Sep-2015
  58       5914331           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          7-Jun-95         2-Jul-2017
  59       5922695           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          25-Jul-97        25-Jul-2017
  60       5935946           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          25-Jul-97        25-Jul-2017
  61       5977089           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          6-Nov-98         25-Jul-2017
  62       6043230           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          19-May-99        25-Jul-2017
  63       6639071           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          19-Oct-01        14-Feb-2018
  64       6642245           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          7-Jun-95         4-Nov-2020
  65       6703396           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          7-Jun-95         9-Mar-2021
  66       6939964           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          24-Jun-04        20-Jan-2018
  67       7402588           Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate   Atripla       Gilead      NRTIs                                          28-Mar-06        1-Feb-2010
  68       5210085           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          22-Feb-91        11-May-10
  69       5814639           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          16-Feb-93        29-Sep-15
  70       5914331           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          7-Jun-95         2-Jul-17
  71       5922695           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          25-Jul-97        25-Jul-17
  72       5935946           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          25-Jul-97        25-Jul-17
  73       5977089           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          6-Nov-98         25-Jul-17
  74       6043230           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          19-May-99        25-Jul-17
  75       6642245           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          7-Jun-95         4-Nov-20
  76       6703396           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          13-Mar-95        9-Mar-21
  77       7402588           Emtricitabine; Tenofovir Disoproxil Fumarate              Truvada       Gilead      NRTIs                                          28-Mar-06        1-Feb-10
  78       5563142           Delavirdine Mesylate                                      Rescriptor    Agouron     NNRTIs                                         22-Feb-94        8-Oct-2013
  79       6177101           Delavirdine Mesylate                                      Rescriptor    Agouron     NNRTIs                                         7-Jun-99         7-Jun-2019
  80       6238695           Efavirenz                                                 Sustiva       BMS         NNRTIs                                         6-Apr-99         6-Apr-2019
  81       6555133           Efavirenz                                                 Sustiva       BMS         NNRTIs                                         2-Apr-01         6-Apr-2019
  82       6878717           Etravirine                                                Intelence     Tibotec     NNRTIs                                         1-Nov-99         5-Nov-2019
  83       7037917           Etravirine                                                Intelence     Tibotec     NNRTIs                                         5-Aug-03         5-Nov-2019
  84       5366972           Nevirapine                                                Viramune      BI          NNRTIs                                         13-Jul-93        22-Nov-2011
  85       5464933           Enfuvirtide                                               Fuzeon        Roche       Fusion Inhibitor                               7-Jun-93         7-Jun-2013
  86       6133418           Enfuvirtide                                               Fuzeon        Roche       Fusion Inhibitor                               6-Nov-95         17-Nov-2014
  87       6475491           Enfuvirtide                                               Fuzeon        Roche       Fusion Inhibitor                               19-Dec-96        7-Jun-2015
  88       6586430           Maraviroc                                                 Selzentry     Pfizer      Entry Inhibitors-CCR5 co-receptor antagonist   1-Dec-99         1-Dec-2019
  89       6667314           Maraviroc                                                 Selzentry     Pfizer      Entry Inhibitors-CCR5 co-receptor antagonist   25-May-01        25-May-2021
  90       7368460           Maraviroc                                                 Selzentry     Pfizer      Entry Inhibitors-CCR5 co-receptor antagonist   3-Oct-03         25-Nov-2022
  91       7169780           Raltegravir Potassium                                     Isentress     Merck       HIV integrase strand transfer inhibitors       1-May-03         9-Oct-2023
  92       7217713           Raltegravir Potassium                                     Isentress     Merck       HIV integrase strand transfer inhibitors       24-Jul-06        21-Oct-2022
  93       7435734           Raltegravir Potassium                                     Isentress     Merck       HIV integrase strand transfer inhibitors       19-Dec-06        21-Oct-2022

Souce:

Electronic Orange Book updated Feb, 2009.

###### 

Summary of US Patents on FDA Approved ART Drugs Company Wise

  S. No.      Company   No. of Patents   Name of the Drug   Class
  ----------- --------- ---------------- ------------------ ----------------------------------------------
  1           GSK       4                Agenerase          PI
  2           GSK       2                Lexiva             PI
  3           GSK       4                Ziagen             NRTIs
  4           GSK       4                Epzicom            NRTIs
  5           GSK       2                Epivir             NRTIs
  6           GSK       1                Combivir           NRTIs
  7           BMS       2                Reyataz            PI
  8           BMS       2                Sustiva            NNRTIs
  9           Tibotec   3                Prezista           PI
  10          Tibotec   2                Intelence          NNRTIs
  11          Merck     3                Isentress          HIV integrase strand transfer inhibitors
  12          Merck     2                Crixivan           PI
  13          Abbott    20               Kaletra            PI
  14          Agouron   3                Viracept           PI
  15          Agouron   2                Rescriptor         NNRTIs
  16          Roche     1                Invirase           PI
  17          Roche     3                Fuzeon             Fusion Inhibitor
  18          BI        4                Aptivus            PI
  19          BI        1                Viramune           NNRTIs
  20          Gilead    15               Atripla            NRTIs
  21          Gilead    10               Truvada            NRTIs
  22          Pfizer    3                Selzentry          Entry Inhibitors-CCR5 co-receptor antagonist
  **Total**   **93**                                        

Souce:

Electronic Orange Book updated Feb, 2009.

###### 

Data on Drug Licensing of Originator Companies to Non-U.S. Countries

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S. No.   Patent Holder   Drug                                                 Non US Companies Licensed                                                                                                                                                                                                                                                                                                                                                                                                        India
  -------- --------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        GSK             lamivudine, zidovudine and lamivudine + zidovudine   Cipla Medpro - the third largest generic drug company in South Africa; Biotech Laboratories - a subsidiary of Afrika Biopharma to supply generic antiretrovirals to both the public and private sectors throughout sub-Saharan Africa; Feza Pharmaceuticals, Thembalami Pharmaceuticals and Aspen Pharmacare South Africa, and Cosmos Limited in Kenya \[[1](#T6FN2){ref-type="table-fn"} & [2](#T6FN3){ref-type="table-fn"}\]   NIL

  2        Tibotec         darunavir (Prezista)                                 Aspen Pharmacare, South Africa \[[3](#T6FN4){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                                              Emcure Pharmaceuticals Ltd, India

  3        BMS             atazanavir (Reyataz)                                 Aspen Pharmacare, South Africa \[[4](#T6FN5){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                                              Emcure Pharmaceuticals Ltd, India

  4        BMS             stavudine and didanosine                             Aurobindo Pharma, in 49 countries including South Africa \[[5](#T6FN6){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                    Aurobindo Pharma, India

  5        Gilead          tenofovir DF                                         Aspen Pharmacare, South Africa \[[6](#T6FN7){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                                              Emcure Pharmaceuticals Ltd., Hetero Drugs Ltd., Strides Arcolab Ltd, Alkem Laboratories\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Aurobindo Pharma FDC, JB Chemicals & Pharmaceuticals, Matrix, Medchem International, Ranbaxy, Shasun Chemicals & Drugs

  6        Gilead          tenofovir disoproxil fumarate and emtricitabine      Aspen Pharmacare, South Africa, sold in 95 developing countries \[[7](#T6FN8){ref-type="table-fn"} & [8](#T6FN9){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                          \*Licensing information not available; Company manufacturing;Matrix Laboratories, Aurobindo

  7        Pfizer          delavirdine                                          not-for-profit group the Concept Foundation and the International Dispensary Association, Thailand \[[9](#T6FN10){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                         NIL

  8        Merck           efavirenz                                            Aspen Pharmacare, South Africa \[[10](#T6FN11){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                                            \*Licensing information not available; Company manufacturing; Aurobindo, Cipla Limited, Strides Arcolab, Matrix Laboratories, Emcure Pharmaceuticals, Hetero Drugs

  9        GSK & BI        lamivudine+ stavudine+ nevirapine (Triomune)         Enaleni Pharmaceuticals, a subsidiary of Indian generic drugs manufacturer Cipla, South Africa \[[11](#T6FN12){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                            NIL

  10       BI              nevirapine                                           Aspen Pharmacare, South Africa \[[12](#T6FN13){ref-type="table-fn"}\]                                                                                                                                                                                                                                                                                                                                                            \*Licensing information not available; Company manufacturing; Ranbaxy, Aurobindo, Cipla, Strides Arcolabs, Hetero Drugs, Matrix Laboratories
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sources:

[www.thebodypro.com/content/art11014.html - 20k -](www.thebodypro.com/content/art11014.html - 20k -)

<http://www.empowermentsa.co.za/betalk.php?myid=27>

<http://www.tibotec.com/bgdisplay.jhtml?itemname=dw_leftblock1>

[www.medicalnewstoday.com/articles/38017.php - 59k](www.medicalnewstoday.com/articles/38017.php - 59k)

[www.haiafrica.org/index.php?option=com_content&task=view&id=105&Itemid=1 - 31k](www.haiafrica.org/index.php?option=com_content&task=view&id=105&Itemid=1 - 31k)

<http://www.gilead.com/access_partnerships>

<http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=700521&highlight>

<http://www.aegis.com/NEWS/BW/2005/BW050411.html>

<http://www.thebodypro.com/content/art11680.html>

[www.medicalnewstoday.com/articles/27787.php - 53k](www.medicalnewstoday.com/articles/27787.php - 53k)

<http://icommons.org/article_print/a-sick-state-access-to-medicine-in-south-africa>

<http://www.essentialdrugs.org/edrug/archive/200312/msg00017.php>
